Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme

Klautke, Günther; Schütze, Michael; Bombor, I; Benecke, R.; Piek, Jürgen; Fietkau, Rainer

doi:10.1007/s11060-005-9028-6

Cited by 18 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 CPT-11 and topotecan have also shown some efficacy in the treatment of glioma. [25][26][27] However, low levels of efficacy when administered as a single agent and major toxicities such as colitis and interstitial pneumonia potentially limit their use for this purpose. 28,29 CKD-602 is a potent topoisomerase 1 inhibitor that does not have the poor water solubility and toxicity of its parent drug, camptothecin.…”

Section: Discussionmentioning

confidence: 99%

Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model

Kim

Lee

Kim

et al. 2012

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model

Kim

Lee

Kim

et al. 2012

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…Moreover, in children affected by malignant brain-stem tumors, the association of carboplatin [83], paclitaxel in continuous infusion [84], or a combination of multiple drugs such as VP16, ifosfamide, CDDP, dactinomycin [85], to radiation therapy did not improve the prognosis in terms of overall survival or progression-free survival. In patients affected by high-grade glioma (mainly glioblastoma) Yang, et al [86] experienced the association of procarbazine, CCNU and VCR plus radiotherapy, Klantke, et al [87] topotecan in continuous infusion plus hyperfractionated radiotherapy (total dose 45.5 Gy + 12.25 Gy), Stupp, et al [88] radiotherapy plus continuous daily temozolomide. These authors found a significant survival benefit with acceptable toxicity.…”

Section: Concurrent Chemoradiotherapymentioning

confidence: 99%

Different Treatment Strategies for Pediatric Brain Tumors

Fiorillo

2008

CPR

View full text Add to dashboard Cite

Malignant brain tumors are characterized by high local aggressiveness and tendency to metastasize within the central nervous system (CNS), and rarely outside it. Surgical approach represented and still represents the mainstay of treatment strategies. However, in the majority of cases, gross total resection is recommended to achieve long event-free survival and eventually the cure. In recent years neoadjuvant chemotherapy and adjuvant post-surgical radiotherapy and chemotherapy have gained relevance in facilitating complete surgical removal and in achieving and consolidating complete remission of such tumors. Post-surgical radiation therapy still represents the basic adjuvant treatment for children over three years with standard risk, non metastatic medulloblastoma. This approach is also considered a very important tool for children affected by ependymoma. However, associated chemotherapy is also needed when reduced doses of radiation therapy are administered, in cases of tumors characterized by a more aggressive biologic behaviour, such as high grade gliomas, and metastatic tumors of any origins. The majority of CNS tumors are of neuroepithelial origin and as such responsive to many antineoplastic drugs, like alkylating agents, antimetabolites, and alkaloids. However, in order to reach tumor cells inside the CNS these drugs have to overcome the blood brain barrier. A number of interesting tools able to disrupt or bypass the barrier, such as ionizing radiations, osmotic procedures or the liposomal technology applied to antiblastic drugs, exists. Starting from a dose of radiation of 30 Gy the permeability of an irradiated area is significantly increased compared to that of the unirradiated surrounding cerebral tissue. Many present treatment regimens include concurrent radiotherapy and chemotherapy in the post-surgical phase, and encouraging results have been reported. In the future better results will certainly come from modern technologies applied to radiation therapy, such as tomo-therapy, and from discovery of new drugs or alternative methods of administration of conventional ones.

show abstract

“…DFS: rezidivfreies Überleben; OS: Gesamtüberleben. [14]. Topotecan (0.5 mg/m 2 /d) was given simultaneously to radiotherapy as CVI over 21 days.…”

Section: Tabellementioning

confidence: 99%

Postoperative Radiotherapy of Glioblastoma Multiforme

et al. 2007

View full text Add to dashboard Cite

show abstract

Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme

Cited by 18 publications

References 29 publications

Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model

Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model

Different Treatment Strategies for Pediatric Brain Tumors

Postoperative Radiotherapy of Glioblastoma Multiforme

Contact Info

Product

Resources

About